| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tananbaum James B. |
10% Owner |
– – • |
2019-12-03 |
4 |
OE |
$30.00 |
$798,000 |
I/I |
26,600 |
1,472,500 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-11-26 |
4 |
OE |
$30.00 |
$132,000 |
I/I |
4,400 |
1,445,900 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-11-15 |
4 |
OE |
$30.00 |
$597,000 |
I/I |
19,900 |
1,441,500 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-11-14 |
4 |
OE |
$30.00 |
$171,000 |
I/I |
5,700 |
1,421,600 |
|
- |
|
| Hollander David |
Chief R&D Officer |
• – – |
2019-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-11-07 |
4 |
OE |
$30.00 |
$450,000 |
I/I |
15,000 |
1,415,900 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2019-09-09 |
4 |
B |
$18.93 |
$498,953 |
D/D |
26,250 |
197,631 |
2.81 |
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2019-09-09 |
4 |
B |
$19.93 |
$100,447 |
D/D |
5,040 |
339,446 |
2.74 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-09-05 |
4 |
B |
$18.42 |
$289,194 |
I/I |
15,700 |
2,350,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-09-04 |
4 |
B |
$18.48 |
$1,851,696 |
I/I |
100,200 |
1,400,900 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-09-03 |
4 |
B |
$20.54 |
$1,040,741 |
I/I |
50,000 |
2,325,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-30 |
4 |
B |
$21.36 |
$534,000 |
I/I |
25,000 |
2,275,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-23 |
4 |
B |
$23.42 |
$896,986 |
I/I |
38,300 |
2,250,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-22 |
4 |
B |
$23.68 |
$158,656 |
I/I |
6,700 |
2,212,177 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-21 |
4 |
B |
$23.25 |
$26,807 |
I/I |
1,153 |
2,205,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-20 |
4 |
B |
$23.21 |
$1,160,500 |
I/I |
50,000 |
2,204,324 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-19 |
4 |
B |
$23.34 |
$89,789 |
I/I |
3,847 |
2,154,324 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-16 |
4 |
B |
$24.23 |
$2,423,000 |
I/I |
100,000 |
2,150,477 |
1.5 |
- |
|
| Larocca John |
General Counsel |
• – – |
2019-08-14 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
31,458 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-14 |
4 |
B |
$23.73 |
$2,373,000 |
I/I |
100,000 |
2,050,477 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-13 |
4 |
B |
$24.92 |
$6,337,342 |
I/I |
250,000 |
1,310,000 |
1.5 |
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,493,636 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2019-08-12 |
4 |
B |
$24.43 |
$4,630,829 |
I/I |
189,555 |
1,060,000 |
1.5 |
- |
|
| Goldberg Murray A |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
8,050 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750 |
6,350 |
|
- |
|
333 Records found
|
|
Page 6 of 14 |
|
|
